SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives $11.88 Consensus Target Price from Brokerages

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $12.00.

Several brokerages have issued reports on SABS. Chardan Capital upped their price target on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of SAB Biotherapeutics in a report on Monday, June 15th. Wall Street Zen lowered shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Jefferies Financial Group assumed coverage on shares of SAB Biotherapeutics in a research report on Wednesday, May 20th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Leerink Partners upped their price target on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, June 15th.

Institutional Trading of SAB Biotherapeutics

Several large investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. bought a new stake in SAB Biotherapeutics in the 1st quarter valued at about $29,000. State of Wyoming bought a new stake in SAB Biotherapeutics in the 4th quarter valued at about $34,000. ADAR1 Capital Management LLC increased its position in SAB Biotherapeutics by 75.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after buying an additional 11,344 shares in the last quarter. State Street Corp bought a new stake in SAB Biotherapeutics in the 4th quarter valued at about $49,000. Finally, Fifth Lane Capital LP bought a new stake in SAB Biotherapeutics in the 4th quarter valued at about $56,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Down 0.9%

Shares of NASDAQ:SABS opened at $3.84 on Monday. The company has a fifty day moving average of $3.71 and a 200-day moving average of $3.85. The company has a market capitalization of $293.38 million, a PE ratio of -1.82 and a beta of 0.54. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. SAB Biotherapeutics has a 52-week low of $1.67 and a 52-week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). On average, equities analysts predict that SAB Biotherapeutics will post -1.19 EPS for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.